Market Synopsis:

Market Research Future (MRFR)’s study reveals that the Diabetic Retinopathy Market Research Report - Global Forecast till 2025 is anticipated to expand at a CAGR of 5.2% during the forecast period 2017 to 2023.

 

The rising burden of diabetes is prognosticated to emerge as the driving force of market growth. In addition, rising awareness about the disease has intensified the need for advanced diagnostic tests for early diagnosis. This, in turn, is forecasted to accelerate the revenue creation for the market participants.

Changes in lifestyle are fueling the threat of diabetes across the world. It is likely to influence the growth of the diabetic retinopathy market positively in the forthcoming years. Key players are investing in research & development for bringing technologically advanced devices and diagnostics in order to treat the disease effectively. It is presumed to encourage the expansion of the diabetic retinopathy market over the next few years.

The growing geriatric population is supposed to favor the proliferation of the market. On the flip side, inaccuracy of some diagnostic tests, lack of awareness about the disease, and low healthcare expenditure in developing nations are prognosticated to check the expansion of the diabetic retinopathy market in the through the assessment period.

Competitive Dashboard:

Some of the key players profiled in the report are Novartis AG (Germany), Regeneron Pharmaceuticals Inc. (U.S.), Kowa Group (Japan), Bayer (Germany), ThromboGenics (U.S.), Sirnaomics (U.S.), Glycadia Pharmaceuticals (U.S.), Actavis Plc (U.K.), Ampio Pharmaceuticals (U.S.), Genentech (U.S.), Alimera Sciences (U.S.), and BCN Peptides (Spain).

Industry News:

In January 2019, Brazilian and Australian researchers have developed an algorithm that leverages artificial intelligence technology for spotting key marker of diabetic retinopathy with 98% accuracy.

In January 2019, a camp was organized in Hyderabad, India, under the auspices of Indian Institute of Public Health (IIPH, Hyderabad) for raising awareness about diabetic retinopathy.

In December 2018, Google has developed an AI model that detects diabetic retinopathy with an accuracy of human retinal specialists. It is rolling out its diabetic retinopathy initiative in India with Verilywhich works on life sciences research and development.

In April 2018, The U.S. Food & Drug Administration (FDA) has permitted the marketing of the first AI-based device that facilitates the detection of diabetic retinopathy.

Diabetic Retinopathy Market Research Report: Information by Type (Non-proliferative and Proliferative), Treatment (Anti-VEGF Drugs, Laser Photocoagulation, Vitreoretinal Surgery, Steroid Injection), by End User (Hospitals, Ambulatory Surgical Centers, Others) and Region (Americas, Europe, Asia-Pacific and Middle East & Africa) - Forecast till 2025 : https://www.marketresearchfuture.com/reports/diabetic-retinopathy-market-5792